HOME >> MEDICINE >> NEWS
Advances in Uterine Leiomyoma Research: 2nd NIH International Congress

WHAT: The National Institutes of Health will host "Advances in Uterine Leiomyoma Research: 2nd NIH International Congress" on February 24 25. This conference will bring together researchers working in the fields of biomedicine, epidemiology, basic research, therapeutics, and translational medicine to foster an exchange of scientific information among members of the uterine leiomyoma (fibroids) research and health care communities. Fibroids are the most common gynecologic neoplasm in women of reproductive age and the leading cause of hysterectomy in the United States. Topics to be covered include Clinical Experiences and Therapeutic Strategies, Epidemiology, Clinical Trials, Pathogenesis of Smooth Muscle Tumors, and Molecular and Genetics Characteristics.

WHEN: February 24-25, 2005

WHERE: Natcher Conference Center, National Institutes of Health Bethesda, MD 20892

WHO: This conference will be co-chaired by Dr. Vivian Pinn, Associate Director for Women's Health and Director, Office of Research on Women's Health (ORWH), NIH and Dr. Kenneth Olden, Director, National Institute of Environmental Health Sciences, NIH. Program co-chairs include Dr. J. Carl Barrett, National Cancer Institute (NCI), Drs. Estella Parrott and James Segars, National Institute of Child Health and Human Development (NICHD), and Dr. Barbara J. Davis, AstraZeneca. Participants will represent academia, medical centers, government, industry, and advocacy groups.

NOTE TO EDITORS: This congress is a joint effort within the Department of Health and Human Services, including the NIH ORWH, NIEHS, NICHD, NCI, National Institute of Biometry and Biomedical Sciences (NIBIB), National Center for Research Resources (NCRR), and the following DHHS entities: Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), Health Research and Services Administration (HRS
'"/>

Contact: Vicki Malick, NIH Office of Research on Womens Health
301-402-1770
NIH/Office of the Director
17-Feb-2005


Page: 1 2

Related medicine news :

1. Advances in plasma physics at Annual APS Meeting
2. Advances in plasma physics at Annual APS Meeting
3. Advances in understanding brain circuits responsible for tics in Tourettes shed light on disorder
4. Advances in Skeletal Anabolic Agents for the Treatment of Osteoporosis: A scientific meeting
5. Advances emerging in hepatitis management
6. Advances in prevention and treatment research hold promise for pipeline
7. Advances in MRI imaging may lead to new standards for faster diagnosis of multiple sclerosis
8. Peanut Allergy: Major Advances in Treatment and Education
9. "Radical" Discovery Advances Medicine and Plastics
10. Advances in On the Spot tests have huge public health implications
11. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... 13, 2017 , ... “America On The Brink”: the Christian history of the ... is the creation of published author, William Nowers. Captain Nowers and his wife, ... he spent thirty years in the Navy. Following his career as a naval ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... ZirMed Inc ., a recognized leader in cloud-based revenue cycle ... ranked #1 by its users for the seventh consecutive year ... ZirMed was recognized as the top-ranked end-to-end revenue cycle management ... 200 beds and holds one of the longest #1 ranking ... ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017   ... for global supply chains, has published the first annual edition of its ... of more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings ... 2016. ... CSR Risk & Performance Index ...
Breaking Medicine Technology:
Cached News: